Generics snafus give Big Pharma a windfall, but cost U.S. patients billions

Save

FDA actions against India's Ranbaxy Laboratories ostensibly are keeping U.S. consumers safer, but much poorer. The plant bans have also shined a spotlight on how complex drug laws in the U.S. can work against consumers' best interests.